USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity
Shimin An, Ling‐Ping Zhao, Li‐Jun Shen, Siyuan Wang, Kuo Zhang, Yu Qi, Jilin Zheng, Xiao‐Jing Zhang, Xue‐Yong Zhu, Rong Bao, Ling Yang, Yue‐Xin Lu, Zhi‐Gang She, Yi‐Da Tang – 17 July 2017 – Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, impaired insulin sensitivity, and chronic low‐grade inflammation. However, the pathogenic mechanism of NAFLD is poorly understood, which hinders the exploration of possible treatments.